Matches in SemOpenAlex for { <https://semopenalex.org/work/W2277033688> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2277033688 endingPage "12" @default.
- W2277033688 startingPage "2507" @default.
- W2277033688 abstract "To evaluate the sensitivity and specificity of BTAstat, NMP22, HA, Survivin, CD44v6, VEGF, and VUC in detection of bladder cancer.We detect VUC, BTAstat, NMP22, HA, Survivin, CD44v6, VEGF in the urine of 10 normal case (healthy volunteers), 11 benign urological diseases patients and 52 bladder cancer patients. The sensitivity, specificity the coefficient of variation, the examining time duration and the checking costs of each marker and combined markers were assessed to evaluate the clinical value.There is a significant difference between the cancer group and the two control groups. The overall sensitivity and specificity of urinary tumor markers were: 42.3% and 100% for VUC; 78.8% and 90.5% for BTAstat; 76.9% and 81.0% for NMP22; 86.5% and 90.5% for HA; 67.3% and 85.7% for Survivin; 50.5% and 85.7% for CD44 and 69.2% and 95.2% for VEGF. The highest sensitivity of combined markers was 96.2% for NMP22 + HA and HA + CD44v6, whereas the lowest sensitivity of combined markers was 67.3% for VUC + CD44v6. The highest specificity (95.2%) was the combined use of VUC + NMP22 and combined use of VUC + VEGF, whereas, method that achieved the lowest specificity (66.7%) was the combined use of HA + Survivin. The most convenient examining method was the detection for BTAstat; the lowest cost examining method was the detection for HA; methods which had the best repeatability were the detection for BTAstat and urine cytology examination.Each marker had achieved its obvious clinical value in diagnosis of bladder cancer. The sensitivity of all the markers was increased with the progression of tumor grades and clinical stages, except the CD44v6. The combined use of BATstat and HA is the best examining method concerning sensitivity, specificity, feasibility and cost in each different method." @default.
- W2277033688 created "2016-06-24" @default.
- W2277033688 creator A5000121887 @default.
- W2277033688 creator A5024598893 @default.
- W2277033688 creator A5052135215 @default.
- W2277033688 creator A5081733705 @default.
- W2277033688 creator A5086730562 @default.
- W2277033688 creator A5090068965 @default.
- W2277033688 date "2005-09-14" @default.
- W2277033688 modified "2023-09-23" @default.
- W2277033688 title "[Clinical evaluation of BTAstat, NMP22, HA, survivin, CD44v6, vEGF and VUC in bladder cancer diagnosis]." @default.
- W2277033688 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16321281" @default.
- W2277033688 hasPublicationYear "2005" @default.
- W2277033688 type Work @default.
- W2277033688 sameAs 2277033688 @default.
- W2277033688 citedByCount "2" @default.
- W2277033688 crossrefType "journal-article" @default.
- W2277033688 hasAuthorship W2277033688A5000121887 @default.
- W2277033688 hasAuthorship W2277033688A5024598893 @default.
- W2277033688 hasAuthorship W2277033688A5052135215 @default.
- W2277033688 hasAuthorship W2277033688A5081733705 @default.
- W2277033688 hasAuthorship W2277033688A5086730562 @default.
- W2277033688 hasAuthorship W2277033688A5090068965 @default.
- W2277033688 hasConcept C121608353 @default.
- W2277033688 hasConcept C126322002 @default.
- W2277033688 hasConcept C126894567 @default.
- W2277033688 hasConcept C1491633281 @default.
- W2277033688 hasConcept C154020017 @default.
- W2277033688 hasConcept C185592680 @default.
- W2277033688 hasConcept C2775975398 @default.
- W2277033688 hasConcept C2777548846 @default.
- W2277033688 hasConcept C2780026642 @default.
- W2277033688 hasConcept C2780352672 @default.
- W2277033688 hasConcept C2780932548 @default.
- W2277033688 hasConcept C29456083 @default.
- W2277033688 hasConcept C43617362 @default.
- W2277033688 hasConcept C55493867 @default.
- W2277033688 hasConcept C71924100 @default.
- W2277033688 hasConcept C77411442 @default.
- W2277033688 hasConceptScore W2277033688C121608353 @default.
- W2277033688 hasConceptScore W2277033688C126322002 @default.
- W2277033688 hasConceptScore W2277033688C126894567 @default.
- W2277033688 hasConceptScore W2277033688C1491633281 @default.
- W2277033688 hasConceptScore W2277033688C154020017 @default.
- W2277033688 hasConceptScore W2277033688C185592680 @default.
- W2277033688 hasConceptScore W2277033688C2775975398 @default.
- W2277033688 hasConceptScore W2277033688C2777548846 @default.
- W2277033688 hasConceptScore W2277033688C2780026642 @default.
- W2277033688 hasConceptScore W2277033688C2780352672 @default.
- W2277033688 hasConceptScore W2277033688C2780932548 @default.
- W2277033688 hasConceptScore W2277033688C29456083 @default.
- W2277033688 hasConceptScore W2277033688C43617362 @default.
- W2277033688 hasConceptScore W2277033688C55493867 @default.
- W2277033688 hasConceptScore W2277033688C71924100 @default.
- W2277033688 hasConceptScore W2277033688C77411442 @default.
- W2277033688 hasIssue "35" @default.
- W2277033688 hasLocation W22770336881 @default.
- W2277033688 hasOpenAccess W2277033688 @default.
- W2277033688 hasPrimaryLocation W22770336881 @default.
- W2277033688 hasRelatedWork W1977602802 @default.
- W2277033688 hasRelatedWork W2040074305 @default.
- W2277033688 hasRelatedWork W2055610704 @default.
- W2277033688 hasRelatedWork W2066516978 @default.
- W2277033688 hasRelatedWork W2368596864 @default.
- W2277033688 hasRelatedWork W2399817806 @default.
- W2277033688 hasRelatedWork W2407532893 @default.
- W2277033688 hasRelatedWork W2412595841 @default.
- W2277033688 hasRelatedWork W2789352678 @default.
- W2277033688 hasRelatedWork W2913626256 @default.
- W2277033688 hasVolume "85" @default.
- W2277033688 isParatext "false" @default.
- W2277033688 isRetracted "false" @default.
- W2277033688 magId "2277033688" @default.
- W2277033688 workType "article" @default.